BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34773595)

  • 1. Predictors of disease recurrence after curative surgery for nonfunctioning pancreatic neuroendocrine neoplasms (NF-PanNENs): a systematic review and meta-analysis.
    Andreasi V; Ricci C; Partelli S; Guarneri G; Ingaldi C; Muffatti F; Crippa S; Casadei R; Falconi M
    J Endocrinol Invest; 2022 Apr; 45(4):705-718. PubMed ID: 34773595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The number of positive nodes accurately predicts recurrence after pancreaticoduodenectomy for nonfunctioning neuroendocrine neoplasms.
    Partelli S; Javed AA; Andreasi V; He J; Muffatti F; Weiss MJ; Sessa F; La Rosa S; Doglioni C; Zamboni G; Wolfgang CL; Falconi M
    Eur J Surg Oncol; 2018 Jun; 44(6):778-783. PubMed ID: 29610023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations.
    Panzuto F; Pusceddu S; Faggiano A; Rinzivillo M; Brighi N; Prinzi N; Riccardi F; Iannicelli E; Maggio I; Femia D; Tafuto S; Manuzzi L; Di Sarno A; Annibale B; de Braud F; Campana D;
    Pancreatology; 2019 Dec; 19(8):1067-1073. PubMed ID: 31587962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of CT findings to predict survival outcomes in patients with pancreatic neuroendocrine neoplasms: a single institutional study of 161 patients.
    Kim DW; Kim HJ; Kim KW; Byun JH; Kim SY; Song KB; Ramaiya NH; Tirumani SH; Hong SM
    Eur Radiol; 2016 May; 26(5):1320-9. PubMed ID: 26253259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative outcomes of pancreatic neuroendocrine neoplasms: A population-based analysis of the SEER database.
    Yang Z; Shi G
    Eur J Surg Oncol; 2022 Oct; 48(10):2181-2187. PubMed ID: 35623986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of intratumoral perfusion analysis for assessing biological features of non-functional pancreatic neuroendocrine neoplasm.
    Notake T; Shimizu A; Kubota K; Sugenoya S; Umemura K; Goto T; Yamada A; Fujinaga Y; Soejima Y
    Langenbecks Arch Surg; 2024 Jan; 409(1):38. PubMed ID: 38221590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs).
    Partelli S; Gaujoux S; Boninsegna L; Cherif R; Crippa S; Couvelard A; Scarpa A; Ruszniewski P; Sauvanet A; Falconi M
    JAMA Surg; 2013 Oct; 148(10):932-9. PubMed ID: 23986355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural history and clinical outcomes of pancreatic neuroendocrine neoplasms based on the WHO 2017 classification; a single-center experience of 30 years.
    Fujimori N; Miki M; Lee L; Matsumoto K; Takamatsu Y; Takaoka T; Teramatsu K; Suehiro Y; Murakami M; Igarashi H; Oono T; Ohtsuka T; Nakamura M; Koga Y; Oda Y; Ito T; Ogawa Y
    Pancreatology; 2020 Jun; 20(4):709-715. PubMed ID: 32360001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Nonfunctional Pancreatic Neuroendocrine Tumors.
    Genç CG; Jilesen AP; Partelli S; Falconi M; Muffatti F; van Kemenade FJ; van Eeden S; Verheij J; van Dieren S; van Eijck CHJ; Nieveen van Dijkum EJM
    Ann Surg; 2018 Jun; 267(6):1148-1154. PubMed ID: 28594340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High minichromosome maintenance protein 7 proliferation indices: a powerful predictor of progression in pancreatic neuroendocrine neoplasms without distant metastasis at the time of surgery.
    Ban X; Yan J; Yu S; Lu Z; Chang X; Jia C; Gao C; Shao H; Wu Y; Mao X; Zhang Y; Li Y; Chen J
    Hum Pathol; 2019 Mar; 85():101-111. PubMed ID: 30447299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Machine learning-based model for prediction and feature analysis of recurrence in pancreatic neuroendocrine tumors G1/G2.
    Murakami M; Fujimori N; Nakata K; Nakamura M; Hashimoto S; Kurahara H; Nishihara K; Abe T; Hashigo S; Kugiyama N; Ozawa E; Okamoto K; Ishida Y; Okano K; Takaki R; Shimamatsu Y; Ito T; Miki M; Oza N; Yamaguchi D; Yamamoto H; Takedomi H; Kawabe K; Akashi T; Miyahara K; Ohuchida J; Ogura Y; Nakashima Y; Ueki T; Ishigami K; Umakoshi H; Ueda K; Oono T; Ogawa Y
    J Gastroenterol; 2023 Jun; 58(6):586-597. PubMed ID: 37099152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Significance and Predictors of Nodal Recurrence After Surgery for Non-Functioning Pancreatic Neuroendocrine Tumors.
    Partelli S; Andreasi V; Peralta Ferreira M; Palumbo D; Muffatti F; Battistella A; Fermi F; Mapelli P; Tamburrino D; Pecorelli N; Crippa S; Falconi M
    Ann Surg Oncol; 2023 Jun; 30(6):3466-3477. PubMed ID: 36774433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery.
    Slagter AE; Ryder D; Chakrabarty B; Lamarca A; Hubner RA; Mansoor W; O'Reilly DA; Fulford PE; Klümpen HJ; Valle JW; McNamara MG
    Surg Oncol; 2016 Sep; 25(3):223-8. PubMed ID: 27566026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival comparison between primary hepatic neuroendocrine neoplasms and primary pancreatic neuroendocrine neoplasms and the analysis on prognosis-related factors.
    Li MX; Li QY; Xiao M; Wan DL; Chen XH; Zhou L; Xie HY; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2019 Dec; 18(6):538-545. PubMed ID: 30981633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. R0 Versus R1 Resection Matters after Pancreaticoduodenectomy, and Less after Distal or Total Pancreatectomy for Pancreatic Cancer.
    Demir IE; Jäger C; Schlitter AM; Konukiewitz B; Stecher L; Schorn S; Tieftrunk E; Scheufele F; Calavrezos L; Schirren R; Esposito I; Weichert W; Friess H; Ceyhan GO
    Ann Surg; 2018 Dec; 268(6):1058-1068. PubMed ID: 28692477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Significance of Lymphatic, Microvascular and Perineural Invasion in Patients With Pancreatic Neuroendocrine Neoplasms.
    Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Matsunaga Y; Shiihara M; Takayama Y; Tahara J; Shimizu K; Tokushige K; Yamamoto M
    Cancer Diagn Progn; 2022; 2(2):150-159. PubMed ID: 35399168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel risk factor panel predicts early recurrence in resected pancreatic neuroendocrine tumors.
    Wang WQ; Zhang WH; Gao HL; Huang D; Xu HX; Li S; Li TJ; Xu SS; Li H; Long J; Ye LY; Wu CT; Han X; Wang XH; Liu L; Yu XJ
    J Gastroenterol; 2021 Apr; 56(4):395-405. PubMed ID: 33742253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pattern of disease recurrence and treatment after surgery for nonfunctioning well-differentiated pancreatic neuroendocrine tumors.
    Partelli S; Landoni L; Andreasi V; Nessi C; Muffatti F; Crippa S; Cingarlini S; Bassi C; Falconi M
    Surgery; 2020 Nov; 168(5):816-824. PubMed ID: 32778411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Role of Examined and Positive Lymph Nodes after Distal Pancreatectomy for Non-Functioning Neuroendocrine Neoplasms.
    Guarneri G; de Mestier L; Landoni L; Partelli S; Gaujoux S; Andreasi V; Nessi C; Dokmak S; Fontana M; Dousset B; Ruszniewski P; Bassi C; Falconi M; Sauvanet A
    Neuroendocrinology; 2021; 111(8):728-738. PubMed ID: 32585667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
    Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.